<DOC>
	<DOC>NCT01708044</DOC>
	<brief_summary>To examine the effects of different fixed pramlintide:insulin dose ratios in subjects with type 1 diabetes on postprandial plasma glucose concentrations</brief_summary>
	<brief_title>Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Pramlintide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Islet Amyloid Polypeptide</mesh_term>
	<criteria>Is 18 to 70 years old Is male, or is female and meets all the following criteria: 1. Not breastfeeding 2. Negative pregnancy test result and, if of childbearing potential, must practice and be willing to continue to practice appropriate birth control Has been diagnosed with type 1 diabetes mellitus for at least 1 year and not achieving glycemic goal while on MDI of insulin Has HbA1c between 7.0% and 9.0% Has been on MDI of regular insulin, at a dose not to exceed 10 units/breakfast for at least 3 months or has been on continuous subcutaneous insulin infusion (CSII), at a dose not to exceed 10 units/breakfast, for at least 3 months and is willing to switch to an MDI insulin regimen for 1 day prior to enrollment and through the study Has a body mass index (BMI) &lt;30 kg/m2 Has experienced recurrent severe hypoglycemia requiring assistance within 6 months before Visit 1 Screening Has a history of hypoglycemia unawareness Has a confirmed diagnosis of gastroparesis Has been treated, is currently being treated, or is expected to require or undergo treatment with the following medications: 1. Any antihyperglycemic agent other than insulin 2. Drugs that directly affect gastrointestinal motility (e.g., anticholinergic agents such as atropine) 3. Drugs that slow the intestinal absorption of nutrients (e.g., Î±glucosidase inhibitors. Has a clinically significant medical condition that could potentially affect study participation and/or personal wellbeing, as judged by the investigator, including but not limited to the following conditions: 1. Hepatic disease 2. Renal disease 3. Gastrointestinal disease 4. Pulmonary disease 5. Organ transplantation 6. Chronic infection (e.g., tuberculosis, human immunodeficiency virus, hepatitis B virus, or hepatitis C virus) Is currently treated or has been previously treated with SYMLIN/pramlintide or has participated in a SYMLIN/pramlintide clinical study within 3 months of Visit 1 (Screening). Has any clinically significant laboratory findings or medical history that may affect successful completion of the study and/or personal wellbeing Has donated blood within 2 months or is planning to donate blood during the study. Has had a major surgery or a blood transfusion within 2 months Has received any investigational drug within 1 month Has known allergies or hypersensitivity to any component of study treatment. Is an immediate family member of personnel directly affiliated with the study at the clinical study site, or is directly affiliated with the study at the clinical study site. Is employed by Amylin Pharmaceuticals, Inc (Amylin) (that is an employee, temporary contract worker, or designee responsible for the conduct of the study).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Pramlintide,</keyword>
	<keyword>insulin,</keyword>
	<keyword>type 1 diabetes,</keyword>
	<keyword>reduction in postprandial glucose,</keyword>
	<keyword>pramlintide:insulin dose-ratio</keyword>
</DOC>